AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

IRON ROAD LTD

0.010

0.000

Volume:719.87K

Turnover:7K

Market Cap:8.40M

PE:-0.08

High:0.010

Open:0.010

Low:0.010

Close:0.010

52wk High:0.060

52wk Low:0.009

Shares:840.19M

Float Shares:216.26M

Volume Ratio:6.21

T/O Rate:0.33%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.119

EPS(LYR):0.006

ROE:-109.99%

ROA:-1.42%

PB:0.21

PE(LYR):1.75

Loading ...

Overview Company News Filings

RBC Adjusts PT on Opus Genetics to $9 From $10, Maintains Outperform Speculative Risk Rating

MT Newswires Live

Opus Genetics Completes Enrollment in Phase 3 Gene Therapy Trial for Rare Blindness Disorder

MT Newswires Live

TD Cowen Initiates Opus Genetics at Buy

MT Newswires Live

Iron Road Ltd-Corporate Update

THOMSON REUTERS

Guggenheim Initiates Opus Genetics at Buy With $16 Price Target

MT Newswires Live

Leerink Partners Initiates Opus Genetics at Outperform With $10 Price Target

MT Newswires Live

Opus Genetics (IRD) Q1 Loss Of US$65.5 Million Intensifies Bearish Community Narratives

Simply Wall St.

Cantor Fitzgerald Initiates Opus Genetics at Overweight With $15 Price Target

MT Newswires Live

Bremworth Secures IRD Clearance in Floorscape Acquisition Process

MT Newswires Live

Chardan Raises Price Target on Opus Genetics to $11 From $9, Keeps Buy Rating

MT Newswires Live

BRIEF-Iron Road Will Recognise Non-Cash Impairment Charge Of A$96.5M In Half-Year

Iron Road Ltd - Will Recognise Non-Cash Impairment Charge of a$96.5M in Half-Year

THOMSON REUTERS

Iron Road - Write-Down After Expert Review on Co's South Australian Central Eyre Iron Project

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigeractivity.com/stock/IRD.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"IRD.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"IRD.AU\",,,,,undefined,":{"symbol":"IRD.AU","market":"AU","secType":"STK","nameCN":"IRON ROAD LTD","latestPrice":0.01,"timestamp":1788136417153,"preClose":0.01,"halted":0,"volume":719872,"delay":0,"changeRate":0,"nameEN":"IRON ROAD LTD","floatShares":216255163,"shares":840192775,"eps":-0.118753,"marketStatus":"Trading","change":0,"latestTime":"08-31 10:44:59 AEST","open":0.01,"high":0.01,"low":0.01,"amount":7199,"amplitude":0,"askPrice":0.011,"askSize":171980,"bidPrice":0.01,"bidSize":3500,"shortable":3,"etf":0,"ttmEps":-0.118753,"tradingStatus":2,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1788156000000},"marketStatusCode":2,"adr":0,"exchange":"ASX","adjPreClose":0.01,"openAndCloseTimeList":[[1788134400000,1788156000000]],"volumeRatio":6.208129,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"IRD.AU","preClose":0.01,"auctionPrice":0.01,"auctionVolume":379872,"auctionTime":1788134351646,"referenceTime":1787913003093,"auction":1,"marketStatus":"盘前竞价","timestamp":1788134351646}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"IRD.AU\",,,,,undefined,":{"symbol":"IRD.AU","floatShares":216255163,"roa":"-1.42%","roe":"-109.99%","lyrEps":0.005699,"volumeRatio":6.208129,"shares":840192775,"dividePrice":0,"high":0.01,"amplitude":0,"preClose":0.01,"low":0.01,"week52Low":0.009,"pbRate":"0.21","psRate":"62.59","week52High":0.06,"institutionHeld":0,"latestPrice":0.01,"committee":-0.960109,"eps":-0.118753,"divideRate":0,"volume":719872,"delay":0,"ttmEps":-0.118753,"open":0.01,"prevYearClose":0.024,"prevWeekClose":0.01,"prevMonthClose":0.01,"prevQuarterClose":0.011,"fiveDayClose":0.009,"twentyDayClose":0.012,"sixtyDayClose":0.014,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IRD.AU\",params:#limit:5,,,undefined,":[{"market":"AU","date":"2020-11-11","symbol":"IRD.AU","type":"split","dateTimestamp":1605013200000,"forFactor":991666,"toFactor":1000000,"ratio":0.991666}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IRD.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IRD.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2657454976","title":"RBC Adjusts PT on Opus Genetics to $9 From $10, Maintains Outperform Speculative Risk Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2657454976","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657454976?lang=en_us&edition=fundamental","pubTime":"2026-08-07 20:35","pubTimestamp":1786106149,"startTime":"0","endTime":"0","summary":"Opus Genetics (IRD) has an average rating of buy and mean price target of $10.71, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IRD","BK4139","BK7129","IRD.AU","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656796513","title":"Opus Genetics Completes Enrollment in Phase 3 Gene Therapy Trial for Rare Blindness Disorder","url":"https://stock-news.laohu8.com/highlight/detail?id=2656796513","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656796513?lang=en_us&edition=fundamental","pubTime":"2026-08-03 20:24","pubTimestamp":1785759877,"startTime":"0","endTime":"0","summary":"Opus Genetics  completed enrollment in its phase 3 registrational trial evaluating OPGx-LCA5, an investigational gene therapy for LCA5-associated inherited retinal disease, a rare condition that can cause blindness, the company said on Monday.The trial was developed in collaboration with the US FDA and could support a future Biologics License Application.Opus expects to begin dosing patients in Q4 and report topline data by the end of 2027. OPGx-LCA5 has received FDA Rare Pediatric Disease, Orphan Drug and RMAT designations, it said.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IRD.AU","BK7129","BK4139","IRD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655692867","title":"TD Cowen Initiates Opus Genetics at Buy","url":"https://stock-news.laohu8.com/highlight/detail?id=2655692867","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655692867?lang=en_us&edition=fundamental","pubTime":"2026-07-29 19:45","pubTimestamp":1785325555,"startTime":"0","endTime":"0","summary":"Opus Genetics (IRD) has an average rating of buy and mean price target of $10.65, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["TD","BK4207","BK4139","GSIB","BK4127","IRD.AU","COWN","BK4585","BK4007","IRD","BK7129","BK4566"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642437102","title":"Iron Road Ltd-Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2642437102","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642437102?lang=en_us&edition=fundamental","pubTime":"2026-06-09 07:14","pubTimestamp":1780960440,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260608:nTUECBWQMJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7129","IRD.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640159752","title":"Guggenheim Initiates Opus Genetics at Buy With $16 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2640159752","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640159752?lang=en_us&edition=fundamental","pubTime":"2026-06-04 18:28","pubTimestamp":1780568896,"startTime":"0","endTime":"0","summary":"Opus Genetics (IRD) has an average rating of buy and mean price target of $10.27, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IRD","BK7129","IRD.AU","BK4139","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637380249","title":"Leerink Partners Initiates Opus Genetics at Outperform With $10 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2637380249","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637380249?lang=en_us&edition=fundamental","pubTime":"2026-05-21 19:11","pubTimestamp":1779361902,"startTime":"0","endTime":"0","summary":"Opus Genetics, Inc. (IRD) has an average rating of buy and mean price target of $10.27, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7129","IRD.AU","BK4139","IRD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635769348","title":"Opus Genetics (IRD) Q1 Loss Of US$65.5 Million Intensifies Bearish Community Narratives","url":"https://stock-news.laohu8.com/highlight/detail?id=2635769348","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635769348?lang=en_us&edition=fundamental","pubTime":"2026-05-14 10:27","pubTimestamp":1778725633,"startTime":"0","endTime":"0","summary":"Opus Genetics (IRD) opened Q1 2026 with revenue of US$2.2 million and a basic EPS loss of US$0.75, putting a clear focus on how much cash the business is burning to support its growth plans. The company has reported quarterly revenue between US$2.9 million and US$4.4 million over the past five periods, while basic EPS losses have ranged from US$0.12 to US$1.16, giving investors a broad view of how the income statement changes as spending shifts. With profitability still some way off and...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ird/opus-genetics/news/opus-genetics-ird-q1-loss-of-us655-million-intensifies-beari","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ird/opus-genetics/news/opus-genetics-ird-q1-loss-of-us655-million-intensifies-beari","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["IRD","BK4139","BK4007","IRD.AU","BK7129"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623128773","title":"Cantor Fitzgerald Initiates Opus Genetics at Overweight With $15 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2623128773","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623128773?lang=en_us&edition=fundamental","pubTime":"2026-03-30 19:43","pubTimestamp":1774871026,"startTime":"0","endTime":"0","summary":"Opus Genetics, Inc. (IRD) has an average rating of buy and mean price target of $10.08, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IRD","BK4139","BK4007","BK7129","IRD.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622050016","title":"Bremworth Secures IRD Clearance in Floorscape Acquisition Process","url":"https://stock-news.laohu8.com/highlight/detail?id=2622050016","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622050016?lang=en_us&edition=fundamental","pubTime":"2026-03-25 06:09","pubTimestamp":1774390188,"startTime":"0","endTime":"0","summary":"Bremworth  has received a binding New Zealand tax ruling from the Inland Revenue Department  on its proposed capital return, clearing a key step in Floorscape's planned acquisition of all the company shares, according to a Wednesday filing with the New Zealand bourse.The ruling satisfies a key condition under the scheme implementation agreement, but the scheme remains subject to other requirements, including clearance from the New Zealand Commerce Commission, approval by the company shareholders, and final high court approval, per the filing.The company said shareholders do not need to take any action at this stage, as reported in the filing.The company's shares fell around 2% in recent Wednesday trade.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","IRD.AU","BK4139","BK7129","IRD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618135352","title":"Chardan Raises Price Target on Opus Genetics to $11 From $9, Keeps Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2618135352","media":"MT Newswires Live","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618135352?lang=en_us&edition=fundamental","pubTime":"2026-03-12 18:43","pubTimestamp":1773312205,"startTime":"0","endTime":"0","summary":"Opus Genetics (IRD) has an average rating of buy and mean price target of $9.45, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks a","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IRD","BK4139","BK4007","BK7129","IRD.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2612993237","title":"BRIEF-Iron Road Will Recognise Non-Cash Impairment Charge Of A$96.5M In Half-Year","url":"https://stock-news.laohu8.com/highlight/detail?id=2612993237","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612993237?lang=en_us&edition=fundamental","pubTime":"2026-02-20 09:24","pubTimestamp":1771550651,"startTime":"0","endTime":"0","summary":"BRIEF-Iron Road Will Recognise Non-Cash Impairment Charge Of A$96.5M In Half-YearFeb 20  - Iron Road Ltd IRD.AX:WILL RECOGNISE NON-CASH IMPAIRMENT CHARGE OF A$96.5M IN HALF-YEARWRITE-DOWN AFTER EXPERT REVIEW ON CO'S SOUTH AUSTRALIAN CENTRAL EYRE IRON PROJECTFurther company coverage: IRD.AX ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260220:nFWN3ZF0JF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7129","IRD.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2612332902","title":"Iron Road Ltd -  Will Recognise Non-Cash Impairment Charge of a$96.5M in Half-Year","url":"https://stock-news.laohu8.com/highlight/detail?id=2612332902","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612332902?lang=en_us&edition=fundamental","pubTime":"2026-02-20 05:22","pubTimestamp":1771536158,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260219:nFWN3ZF0JF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7129","IRD.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2612233248","title":"Iron Road - Write-Down After Expert Review on Co's South Australian Central Eyre Iron Project","url":"https://stock-news.laohu8.com/highlight/detail?id=2612233248","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612233248?lang=en_us&edition=fundamental","pubTime":"2026-02-20 05:22","pubTimestamp":1771536158,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260219:nFWN3ZF0JF:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7129","IRD.AU"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":13,"code":"91000000","status":"200"}]}}